Cargando…
Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma
BACKGROUND: Clear-cell renal cell carcinoma (ccRCC) is the most common malignant kidney cancer. However, the tumor microenvironment and crosstalk involved in metabolic reprogramming in ccRCC are not well-understood. METHODS: We used The Cancer Genome Atlas to obtain ccRCC transcriptome data and clin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tech Science Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208045/ https://www.ncbi.nlm.nih.gov/pubmed/37304236 http://dx.doi.org/10.32604/or.2023.028051 |
_version_ | 1785046587608662016 |
---|---|
author | BAO, WEI HAN, QIANGUANG GUAN, XIAO WANG, ZIJIE GU, MIN |
author_facet | BAO, WEI HAN, QIANGUANG GUAN, XIAO WANG, ZIJIE GU, MIN |
author_sort | BAO, WEI |
collection | PubMed |
description | BACKGROUND: Clear-cell renal cell carcinoma (ccRCC) is the most common malignant kidney cancer. However, the tumor microenvironment and crosstalk involved in metabolic reprogramming in ccRCC are not well-understood. METHODS: We used The Cancer Genome Atlas to obtain ccRCC transcriptome data and clinical information. The E-MTAB-1980 cohort was used for external validation. The GENECARDS database contains the first 100 solute carrier (SLC)-related genes. The predictive value of SLC-related genes for ccRCC prognosis and treatment was assessed using univariate Cox regression analysis. An SLC-related predictive signature was developed through Lasso regression analysis and used to determine the risk profiles of patients with ccRCC. Patients in each cohort were separated into high- and low-risk groups based on their risk scores. The clinical importance of the signature was assessed through survival, immune microenvironment, drug sensitivity, and nomogram analyses using R software. RESULTS: SLC25A23, SLC25A42, SLC5A1, SLC3A1, SLC25A37, SLC5A6, SLCO5A1, and SCP2 comprised the signatures of the eight SLC-related genes. Patients with ccRCC were separated into high- and low-risk groups based on the risk value in the training and validation cohorts; the high-risk group had a significantly worse prognosis (p < 0.001). The risk score was an independent predictive indicator of ccRCC in the two cohorts according to univariate and multivariate Cox regression (p < 0.05). Analysis of the immune microenvironment showed that immune cell infiltration and immune checkpoint gene expression differed between the two groups (p < 0.05). Drug sensitivity analysis showed that compared to the low-risk group, the high-risk group was more sensitive to sunitinib, nilotinib, JNK-inhibitor-VIII, dasatinib, bosutinib, and bortezomib (p < 0.001). Survival analysis and receiver operating characteristic curves were validated using the E-MTAB-1980 cohort. CONCLUSIONS: SLC-related genes have predictive relevance in ccRCC and play roles in the immunological milieu. Our results provide insight into metabolic reprogramming in ccRCC and identify promising treatment targets for ccRCC. |
format | Online Article Text |
id | pubmed-10208045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Tech Science Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102080452023-06-10 Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma BAO, WEI HAN, QIANGUANG GUAN, XIAO WANG, ZIJIE GU, MIN Oncol Res Article BACKGROUND: Clear-cell renal cell carcinoma (ccRCC) is the most common malignant kidney cancer. However, the tumor microenvironment and crosstalk involved in metabolic reprogramming in ccRCC are not well-understood. METHODS: We used The Cancer Genome Atlas to obtain ccRCC transcriptome data and clinical information. The E-MTAB-1980 cohort was used for external validation. The GENECARDS database contains the first 100 solute carrier (SLC)-related genes. The predictive value of SLC-related genes for ccRCC prognosis and treatment was assessed using univariate Cox regression analysis. An SLC-related predictive signature was developed through Lasso regression analysis and used to determine the risk profiles of patients with ccRCC. Patients in each cohort were separated into high- and low-risk groups based on their risk scores. The clinical importance of the signature was assessed through survival, immune microenvironment, drug sensitivity, and nomogram analyses using R software. RESULTS: SLC25A23, SLC25A42, SLC5A1, SLC3A1, SLC25A37, SLC5A6, SLCO5A1, and SCP2 comprised the signatures of the eight SLC-related genes. Patients with ccRCC were separated into high- and low-risk groups based on the risk value in the training and validation cohorts; the high-risk group had a significantly worse prognosis (p < 0.001). The risk score was an independent predictive indicator of ccRCC in the two cohorts according to univariate and multivariate Cox regression (p < 0.05). Analysis of the immune microenvironment showed that immune cell infiltration and immune checkpoint gene expression differed between the two groups (p < 0.05). Drug sensitivity analysis showed that compared to the low-risk group, the high-risk group was more sensitive to sunitinib, nilotinib, JNK-inhibitor-VIII, dasatinib, bosutinib, and bortezomib (p < 0.001). Survival analysis and receiver operating characteristic curves were validated using the E-MTAB-1980 cohort. CONCLUSIONS: SLC-related genes have predictive relevance in ccRCC and play roles in the immunological milieu. Our results provide insight into metabolic reprogramming in ccRCC and identify promising treatment targets for ccRCC. Tech Science Press 2023-04-10 /pmc/articles/PMC10208045/ /pubmed/37304236 http://dx.doi.org/10.32604/or.2023.028051 Text en © 2023 BAO et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article BAO, WEI HAN, QIANGUANG GUAN, XIAO WANG, ZIJIE GU, MIN Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma |
title | Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma |
title_full | Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma |
title_fullStr | Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma |
title_full_unstemmed | Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma |
title_short | Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma |
title_sort | solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208045/ https://www.ncbi.nlm.nih.gov/pubmed/37304236 http://dx.doi.org/10.32604/or.2023.028051 |
work_keys_str_mv | AT baowei solutecarrierrelatedsignatureforassessingprognosisandimmunityinpatientswithclearcellrenalcellcarcinoma AT hanqianguang solutecarrierrelatedsignatureforassessingprognosisandimmunityinpatientswithclearcellrenalcellcarcinoma AT guanxiao solutecarrierrelatedsignatureforassessingprognosisandimmunityinpatientswithclearcellrenalcellcarcinoma AT wangzijie solutecarrierrelatedsignatureforassessingprognosisandimmunityinpatientswithclearcellrenalcellcarcinoma AT gumin solutecarrierrelatedsignatureforassessingprognosisandimmunityinpatientswithclearcellrenalcellcarcinoma |